GlassScriptPhysician profile
Kirit R Shah
NPI 1306827647
$6,989.47
in general payments reported to CMS, 2019-2025
30 companies · $645 in 2025
The $645 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,722 · 2020: $365 · 2021: $1,146 · 2022: $1,251 · 2023: $914 · 2024: $946 · 2025: $645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,200.94 | 2019-2025 | Amplatzer Amulet, Aveir, Cardiomems |
| Medtronic Vascular, INC. | $865.57 | 2019 | |
| Amgen INC. | $740.10 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $412.65 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $248.97 | 2021-2023 | Camzyos |
| Boston Scientific Corporation | $202.88 | 2021 | |
| Medtronic, INC. | $198.45 | 2021-2023 | Hawkone |
| Edwards Lifesciences Corporation | $191.00 | 2019-2024 | Sapien 3 Ultra Resilia |
| Inari Medical, INC. | $158.42 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $150.00 | 2025 | Artix Mt |
| Genzyme Corporation | $149.99 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $148.47 | 2024 | |
| Novartis Pharmaceuticals Corporation | $147.02 | 2019-2022 | |
| Philips North America LLC | $143.40 | 2020 | |
| Penumbra, INC. | $142.57 | 2024 | Penumbra System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $139.66 | 2022 | |
| Abiomed | $129.74 | 2022 | |
| Merck Sharp & Dohme LLC | $113.36 | 2021 | |
| Sanofi-Aventis U.S. LLC | $112.14 | 2019 | |
| Chiesi USA, INC. | $102.27 | 2022-2025 | Cleviprex |
| Opsens INC. | $76.71 | 2022 | |
| Janssen Pharmaceuticals, INC | $48.15 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $40.87 | 2019-2022 | |
| Pfizer INC. | $29.39 | 2019-2024 | |
| Kiniksa Pharmaceuticals, LTD. | $18.62 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $18.49 | 2020 | |
| Kestra Medical Technology Services, INC. | $17.98 | 2024 | Assure Wcd |
| Amarin Pharma, INC. | $16.78 | 2021 | |
| United Therapeutics Corporation | $12.73 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirit Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.